ZURICH (Reuters) – Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.
If the pill is approved, Boston-based Atea will distribute it in the United States and Roche will be responsible for global manufacturing and distribution outside the U.S. market. Atea will get an upfront payment of $350 million in cash from Roche with potential for future milestone payments and royalties.
(Reporting by Michael Shields; Editing by Riham Alkousaa)
